This combined inhibition of Pi3K/mTOR and MEK inhibitors with Omipalisib and Trametinib was assessed in a phase 1b study in 69 patients with advanced solid tumors: the necessity to reduce doses due to frequent toxicities (skin rash 71%, diarrhea 61%) in 42% of the patients probably explained the limited antitumor activity observed with only one partial response and 12 patients with stable disease [55]. The gene discussed is MAP2K7; the disease is exanthem.